| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $669.0M | -3.4% |
| Cost of Revenue | $535.7M | -0.1% |
| R&D Expense | $5.1M | -1.9% |
| SG&A Expense | $90.4M | -4.8% |
| Operating Income | -$98.0M | -5700.5% |
| Pre-tax Income | -$102.5M | -1205.8% |
| Income Tax | $6.8M | +101.0% |
| Net Income | -$109.4M | -871.5% |
| EPS (Basic) | -$1.86 | -933.3% |
| EPS (Diluted) | -$1.86 | -933.3% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $69.9M | +7.0% |
| Accounts Receivable | $202.4M | +4.2% |
| Inventory | $183.4M | -14.6% |
| Current Assets | $495.3M | -0.6% |
| Total Assets | $883.4M | -12.1% |
| Current Liabilities | $266.2M | +68.8% |
| Long-term Debt | $1.7M | -98.7% |
| Total Liabilities |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $105.1M | +129.1% |
| Investing Cash Flow | -$11.1M | -509.1% |
| Financing Cash Flow | -$90.2M | -205.8% |
| $310.2M |
| -4.4% |
| Stockholders' Equity | $573.2M | -15.8% |